BioSpace News Archive

Bolt Biotherapeutics, Inc. today announced that the first patients have been dosed in a Phase 2 dose-expansion clinical trial investigating BDC-1001, a HER2-targeting Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC).

Dyne Therapeutics, Inc today reported financial results for the second quarter of 2023 and business highlights.

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced financial results for the second quarter ended June 30, 2023, and provided a business update.

Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the second quarter ended June 30, 2023 and provided a business update.

Elevation Oncology, Inc. today announced financial results for the second quarter ended June 30, 2023, and highlighted recent business achievements.

BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned, independently operated subsidiary of Bayer AG, and bit.bio, the company coding human cells for novel cures, today announced a collaboration and option agreement for the discovery and manufacture of iPSC-derived regulatory T cells (Tregs) for use in creating therapeutics.

Areteia Therapeutics Announces Publication of Phase II Data of Oral Dexpramipexole in Eosinophilic Asthma.

MindMed Announces Exclusive License Agreement With Catalent for Its Patented Zydis ® Fast-Dissolve Technology for Use with MM-120.

Axcella Therapeutics today announced financial results for the second quarter ended June 30, 2023 and provided a business update.

Sonoma Pharmaceuticals, Inc. today announced the appointment of Dr. Hye Jin Chung MD, MMSc, Assistant Professor of Dermatology at Harvard Medical School in Boston and practicing dermatologist at Beth Israel Deaconess Medical Center, to the company’s Scientific Advisory Board.